Sotera Health reports Q1 2026 results and announces CEO transition

Sotera Health Co

2026-Q1 EPS reported $0.09 vs consensus $0.18 ▼ miss (-49.0%)

Q1 net revenues up 10.0% (6.5% constant currency); net income $27M vs loss $13M in prior year.
Adjusted EBITDA increased 10.5% (6.9% constant currency); Adjusted EPS $0.18, up 29%.
Michael Petras appointed Executive Chairman; Alton Shader named CEO effective May 26, 2026.
Reaffirmed 2026 outlook: net revenue growth 5.0%-6.5% and Adj. EBITDA growth 5.5%-7.0% constant currency.
Added independent directors Rich Kyle and Ken Krause to Board; public float ~90%.

item 2.02item 5.02item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Michael B. Petras, Jr.

Executive Chairman

SHC · Sotera Health Co

Effective: 2026-05-26
Successor: Alton Shader
Filed: May 05, 2026 23:59 UTC

Michael B. Petras, Jr. will transition from his role as CEO of the Company and Chairman of the Board and, on May 1, 2026, the Board appointed Mr. Petras to serve as Executive Chairman of the Board ("Executive Chairman"), as of the Effective Date.

Appointed

Alton Shader

Chief Executive Officer

SHC · Sotera Health Co

Effective: 2026-05-26
Filed: May 05, 2026 23:59 UTC

appointed Alton Shader to serve as Chief Executive Officer of the Company ("CEO") and a Class II director of the Board, effective as of May 26, 2026

Source: SEC EDGAR

accession 0001822479-26-000028

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.